Satisfaction with alemtuzumab in relapsing multiple sclerosis patients : Results from the real-world PRO-ACT study
© The Author(s), 2022..
Background: Patient-reported outcomes are increasingly used in the management of patients with multiple sclerosis to understand the patient's perspective of disease and treatment. These measures provide insights into important factors including treatment satisfaction, physical and psychological function, and quality of life.
Objective: To present results from the real-world PRO-ACT study in patients with multiple sclerosis who switched to alemtuzumab from another disease-modifying therapy.
Methods: This 24-month, prospective, multicenter, observational study had a primary endpoint of change in overall satisfaction, measured using the Treatment Satisfaction Questionnaire for Medication (TSQM) version 1.4. Secondary endpoints included the Multiple Sclerosis Impact Scale-29 (MSIS-29), Modified Fatigue Impact Scale-5 (MFIS-5), and the Patient-Determined Disease Steps (PDDS). Safety was monitored with adverse events (AEs).
Results: Of 199 enrolled patients, improvements were observed in mean TSQM scores for overall satisfaction (baseline, 50.3; year 2, + 13.2; p < 0.0001), effectiveness (49.3 and + 12.2; p < 0.0001), and side effects (77.6 and + 4.5; p = 0.04). Improvements were also observed in MSIS-29 physical (52.4 and -6.0; p < 0.0001), MSIS-29 psychological (53.4 and -7.0; p = 0.0003), and MFIS-5 (12.8 and -1.7; p < 0.0001). Most (95.0%) patients experienced ≥ 1 AE (88.4% mild, 67.8% moderate).
Conclusions: The primary endpoint was met; the safety of alemtuzumab was consistent with pivotal studies.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:8 |
|---|---|
| Enthalten in: |
Multiple sclerosis journal - experimental, translational and clinical - 8(2022), 4 vom: 16. Okt., Seite 20552173221135888 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Wray, Sibyl [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Alemtuzumab |
|---|
| Anmerkungen: |
Date Revised 22.11.2022 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1177/20552173221135888 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM349206783 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM349206783 | ||
| 003 | DE-627 | ||
| 005 | 20231226042054.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1177/20552173221135888 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1163.xml |
| 035 | |a (DE-627)NLM349206783 | ||
| 035 | |a (NLM)36407472 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Wray, Sibyl |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Satisfaction with alemtuzumab in relapsing multiple sclerosis patients |b Results from the real-world PRO-ACT study |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 22.11.2022 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © The Author(s), 2022. | ||
| 520 | |a Background: Patient-reported outcomes are increasingly used in the management of patients with multiple sclerosis to understand the patient's perspective of disease and treatment. These measures provide insights into important factors including treatment satisfaction, physical and psychological function, and quality of life | ||
| 520 | |a Objective: To present results from the real-world PRO-ACT study in patients with multiple sclerosis who switched to alemtuzumab from another disease-modifying therapy | ||
| 520 | |a Methods: This 24-month, prospective, multicenter, observational study had a primary endpoint of change in overall satisfaction, measured using the Treatment Satisfaction Questionnaire for Medication (TSQM) version 1.4. Secondary endpoints included the Multiple Sclerosis Impact Scale-29 (MSIS-29), Modified Fatigue Impact Scale-5 (MFIS-5), and the Patient-Determined Disease Steps (PDDS). Safety was monitored with adverse events (AEs) | ||
| 520 | |a Results: Of 199 enrolled patients, improvements were observed in mean TSQM scores for overall satisfaction (baseline, 50.3; year 2, + 13.2; p < 0.0001), effectiveness (49.3 and + 12.2; p < 0.0001), and side effects (77.6 and + 4.5; p = 0.04). Improvements were also observed in MSIS-29 physical (52.4 and -6.0; p < 0.0001), MSIS-29 psychological (53.4 and -7.0; p = 0.0003), and MFIS-5 (12.8 and -1.7; p < 0.0001). Most (95.0%) patients experienced ≥ 1 AE (88.4% mild, 67.8% moderate) | ||
| 520 | |a Conclusions: The primary endpoint was met; the safety of alemtuzumab was consistent with pivotal studies | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Alemtuzumab | |
| 650 | 4 | |a disease-modifying therapies | |
| 650 | 4 | |a multiple sclerosis | |
| 650 | 4 | |a quality of life | |
| 700 | 1 | |a Jacques, Francois |e verfasserin |4 aut | |
| 700 | 1 | |a Miller, Tamara A |e verfasserin |4 aut | |
| 700 | 1 | |a Nicholas, Jacqueline A |e verfasserin |4 aut | |
| 700 | 1 | |a Arroyo, Rafael |e verfasserin |4 aut | |
| 700 | 1 | |a Travis, Lori |e verfasserin |4 aut | |
| 700 | 1 | |a Khatri, Bhupendra |e verfasserin |4 aut | |
| 700 | 1 | |a Chirieac, Magdalena |e verfasserin |4 aut | |
| 700 | 1 | |a Gandhi, Roopali |e verfasserin |4 aut | |
| 700 | 1 | |a Roesch, Nora |e verfasserin |4 aut | |
| 700 | 1 | |a Rodrigues, Amelie |e verfasserin |4 aut | |
| 700 | 1 | |a Melas-Melt, Lydie |e verfasserin |4 aut | |
| 700 | 1 | |a Rawlings, Andreea M |e verfasserin |4 aut | |
| 700 | 1 | |a Hunter, Samuel F |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Multiple sclerosis journal - experimental, translational and clinical |d 2015 |g 8(2022), 4 vom: 16. Okt., Seite 20552173221135888 |w (DE-627)NLM254462944 |x 2055-2173 |7 nnns |
| 773 | 1 | 8 | |g volume:8 |g year:2022 |g number:4 |g day:16 |g month:10 |g pages:20552173221135888 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1177/20552173221135888 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 8 |j 2022 |e 4 |b 16 |c 10 |h 20552173221135888 | ||